Pharmacokinetics of quinine, quinidine and Cinchonine when given as combination.
Pharmacokinetics of quinine, quinidine and cinchonine when given as a combination were evaluated in Thai patients with falciparum malaria during acute infection and convalescence. The combination of quinine, quinidine and cinchonine was randomly given to thirteen patients at 400 mg or 600 mg (consisting of one-third of each component; 7 patients were enrolled in 400 mg regimen and 6 in 600 mg regimen) intravenously every 8 hours for 7 days. The drug combination was given again at day 35 to define the pharmacokinetics of each drug during convalescence. All patients with the 600 mg regimen had good response with 100% cure rate while patients with the 400 mg regimen had a good initial response but one patient recrudesed on day 46. This particular patient had plasma concentrations of all three drugs lower than the mean values of patients with sensitive responses. The plasma levels of quinine and quinidine obtained from the present study were higher than that expected from one-third of the conventional dose (600 mg) when given alone, suggesting drug combination interaction. The terminal half-lives of each of the three components were prolonged during acute malaria when compared to those obtained during convalescence.
Karbwang
J
J
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Bunnag
D
D
Harinasuta
T
T
Chittamas
S
S
Berth
J
J
Druilhe
P
P
D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002930:Cinchona Alkaloids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D016778:Malaria, Falciparum / Q000097:blood / Q000188:drug therapy*; D008297:Male; D011802:Quinidine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011803:Quinine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016896:Treatment Outcome
D000962:Antimalarials; D002930:Cinchona Alkaloids; D004338:Drug Combinations; D011803:Quinine; D011802:Quinidine; C010086:cinchonine